Literature DB >> 16537417

Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B.

Thomas H Langenickel1, Jens Buttgereit, Ines Pagel-Langenickel, Maren Lindner, Jan Monti, Knut Beuerlein, Nidal Al-Saadi, Ralph Plehm, Elena Popova, Jens Tank, Rainer Dietz, Roland Willenbrock, Michael Bader.   

Abstract

Natriuretic peptides (NP) mediate their effects by activating membrane-bound guanylyl cyclase-coupled receptors A (NPR-A) or B (NPR-B). Whereas the pathophysiological role of NPR-A has been widely studied, only limited knowledge on the cardiovascular function of NPR-B is available. In vitro studies suggest antiproliferative and antihypertrophic actions of the NPR-B ligand C-type NP (CNP). Because of the lack of a specific pharmacological inhibitor, these effects could not clearly be attributed to impaired NPR-B signaling. Recently, gene deletion revealed a predominant role of NPR-B in endochondral ossification and development of female reproductive organs. However, morphological abnormalities and premature death of NPR-B-deficient mice preclude detailed cardiovascular phenotyping. In the present study, a dominant-negative mutant (NPR-BDeltaKC) was used to characterize CNP-dependent NPR-B signaling in vitro and in transgenic rats. Here we demonstrate that reduced CNP- but not atrial NP-dependent cGMP response attenuates antihypertrophic potency of CNP in vitro. In transgenic rats, NPR-BDeltaKC expression selectively reduced NPR-B but not NPR-A signaling. NPR-BDeltaKC transgenic rats display progressive, blood pressure-independent cardiac hypertrophy and elevated heart rate. The hypertrophic phenotype is further enhanced in chronic volume overload-induced congestive heart failure. Thus, this study provides evidence linking NPR-B signaling to the control of cardiac growth.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16537417      PMCID: PMC1450239          DOI: 10.1073/pnas.0510019103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Forced homodimerization by site-directed mutagenesis alters guanylyl cyclase activity of natriuretic peptide receptor B.

Authors:  Thomas Langenickel; Jens Buttgereit; Ines Pagel; Rainer Dietz; Roland Willenbrock; Michael Bader
Journal:  Hypertension       Date:  2003-12-22       Impact factor: 10.190

2.  Increased effects of C-type natriuretic peptide on cardiac ventricular contractility and relaxation in guanylyl cyclase A-deficient mice.

Authors:  Melanie Pierkes; Stepan Gambaryan; Peter Bokník; Suzanne M Lohmann; Wilhelm Schmitz; Regine Potthast; Rita Holtwick; Michaela Kuhn
Journal:  Cardiovasc Res       Date:  2002-03       Impact factor: 10.787

3.  Regulation of the guanylyl cyclase-B receptor by alternative splicing.

Authors:  Naohisa Tamura; David L Garbers
Journal:  J Biol Chem       Date:  2003-09-26       Impact factor: 5.157

4.  Improved systolic ventricular function with normal myocardial mechanics in compensated cardiac hypertrophy.

Authors:  Katashi Okoshi; Henrique Barbosa Ribeiro; Marina Politi Okoshi; Beatriz Bojikian Matsubara; Giancarlo Gonçalves; Reginaldo Barros; Antonio Carlos Cicogna
Journal:  Jpn Heart J       Date:  2004-07

5.  Pressure-independent enhancement of cardiac hypertrophy in atrial natriuretic peptide-deficient mice.

Authors:  Ji An Feng; Gilbert Perry; Tatsuhiko Mori; Tetsuya Hayashi; Suzanne Oparil; Yiu-Fai Chen
Journal:  Clin Exp Pharmacol Physiol       Date:  2003 May-Jun       Impact factor: 2.557

6.  Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts.

Authors:  Ahmad Zahabi; Sylvie Picard; Nadia Fortin; Timothy L Reudelhuber; Christian F Deschepper
Journal:  J Biol Chem       Date:  2003-09-18       Impact factor: 5.157

7.  Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts.

Authors:  Takeshi Horio; Takeshi Tokudome; Toshiyuki Maki; Fumiki Yoshihara; Shin-Ichi Suga; Toshio Nishikimi; Masayasu Kojima; Yuhei Kawano; Kenji Kangawa
Journal:  Endocrinology       Date:  2003-06       Impact factor: 4.736

8.  C-type natriuretic peptide: a selective cardiovascular peptide.

Authors:  A L Clavell; A J Stingo; C M Wei; D M Heublein; J C Burnett
Journal:  Am J Physiol       Date:  1993-02

9.  Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP.

Authors:  Anke C Rosenkranz; Robyn L Woods; Gregory J Dusting; Rebecca H Ritchie
Journal:  Cardiovasc Res       Date:  2003-02       Impact factor: 10.787

10.  Efficiency of transgenic rat production is independent of transgene-construct and overnight embryo culture.

Authors:  Elena Popova; Alexander Krivokharchenko; Detlev Ganten; Michael Bader
Journal:  Theriogenology       Date:  2004-05       Impact factor: 2.740

View more
  46 in total

1.  Arg13 of B-type natriuretic Peptide reciprocally modulates binding to guanylyl cyclase but not clearance receptors.

Authors:  Deborah M Dickey; Kathryn A Barbieri; Christopher M McGuirk; Lincoln R Potter
Journal:  Mol Pharmacol       Date:  2010-06-08       Impact factor: 4.436

2.  miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy.

Authors:  Kun Wang; Bo Long; Jing Zhou; Pei-Feng Li
Journal:  J Biol Chem       Date:  2010-02-21       Impact factor: 5.157

3.  Differential activation of natriuretic peptide receptors modulates cardiomyocyte proliferation during development.

Authors:  Jason R Becker; Sneha Chatterjee; Tamara Y Robinson; Jeffrey S Bennett; Daniela Panáková; Cristi L Galindo; Lin Zhong; Jordan T Shin; Shannon M Coy; Amy E Kelly; Dan M Roden; Chee Chew Lim; Calum A MacRae
Journal:  Development       Date:  2013-12-18       Impact factor: 6.868

4.  Natriuretic peptide receptors and heart failure: to B or not to B blocked?

Authors:  A J Hobbs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-12-06       Impact factor: 3.000

Review 5.  Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides.

Authors:  Camilla Calvieri; Speranza Rubattu; Massimo Volpe
Journal:  J Mol Med (Berl)       Date:  2011-08-09       Impact factor: 4.599

Review 6.  Natriuretic peptides in cardiometabolic regulation and disease.

Authors:  Nora E Zois; Emil D Bartels; Ingrid Hunter; Birgitte S Kousholt; Lisbeth H Olsen; Jens P Goetze
Journal:  Nat Rev Cardiol       Date:  2014-05-13       Impact factor: 32.419

7.  Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes.

Authors:  Robert Lukowski; Sergei D Rybalkin; Florian Loga; Veronika Leiss; Joseph A Beavo; Franz Hofmann
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-08       Impact factor: 11.205

8.  Identification of small molecule NPR-B antagonists by high throughput screening--potential use in heart failure.

Authors:  Trond Bach; Stine Bergholtz; Jon Riise; Eirik Qvigstad; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-12-03       Impact factor: 3.000

Review 9.  Central role of guanylyl cyclase in natriuretic peptide signaling in hypertension and metabolic syndrome.

Authors:  G Martel; P Hamet; Johanne Tremblay
Journal:  Mol Cell Biochem       Date:  2009-11-25       Impact factor: 3.396

10.  Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP.

Authors:  Ondrej Lisy; Brenda K Huntley; Daniel J McCormick; Paul A Kurlansky; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2008-07-01       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.